MedTech Industry Dynamics
MedTech Industry Dynamics
Abbott has received FDA De Novo authorization for its Libre Duo 10 Day system, the world’s first dual glucose-ketone sensing technology designed to monitor glucose and detect rising ketone levels that can lead to diabetic ketoacidosis in people with diabetes.
Meer lezenAbbott and Google Health have announced a multi-year partnership to combine glucose insights from Abbott’s Lingo biowearable with Google’s AI and consumer technology, creating a unified experience for personalized metabolic health guidance in the Google Health app.
Meer lezenCardinal Health has entered into two definitive agreements to acquire AdaptHealth’s Diabetes Health business and Strive Medical for approximately $360 million in cash, expanding its at-Home Solutions platform in diabetes management and urology.
Meer lezenALR Technologies has entered into a Letter of Intent to acquire CGM Medical Technology Singapore and assets of CGM Medical Shenzhen for an aggregate purchase price of US$45 million and 200 million ordinary shares, with the goal of becoming a fully integrated diabetes management company.
Meer lezenFiberSense has announced that its Continuous Glucose Monitoring (CGM) System has obtained CE marking as a Class IIb medical device, paving the way for commercialization as the company prepares for manufacturing scale-up and first deliveries in late 2026.
Meer lezenCeQur has closed a $100 million Series E financing round to accelerate commercial growth for CeQur Simplicity, its mealtime insulin delivery device, as adoption expands across primary care and endocrinology practices nationwide.
Meer lezenAbbott has received CE Mark for Libre Duo and Libre Duo 10 Day, the world’s first dual glucose-ketone continuous sensing systems designed to measure both glucose and ketone levels every minute, helping people with diabetes detect rising ketones that can lead to diabetic ketoacidosis.
Meer lezenEndogenex raises $50 million in Series C extension led by Arboretum Ventures to fund its pivotal ReCET clinical trial and support FDA approval for its novel type 2 diabetes therapy.
Meer lezenembecta has agreed to acquire UK-based Owen Mumford for up to £150 million, aiming to expand its drug-delivery device portfolio and accelerate its transition into a broader medical supplies company.
Meer lezenSenseonics has received EU MDR CE Mark approval for Eversense 365, a one-year implantable continuous glucose monitoring system, paving the way for its commercial launch in several European markets.
Meer lezen
